Free Trial
NASDAQ:MBIO

Mustang Bio Q1 2025 Earnings Report

Mustang Bio logo
$1.24 -0.01 (-0.80%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$1.24 0.00 (0.00%)
As of 06/6/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mustang Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mustang Bio Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Mustang Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Mustang Bio Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Mustang Bio regains compliance with Nasdaq requirement
See More Mustang Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mustang Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mustang Bio and other key companies, straight to your email.

About Mustang Bio

Mustang Bio (NASDAQ:MBIO), a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

View Mustang Bio Profile

More Earnings Resources from MarketBeat